According to incomplete statistics from Innovation Radar, last week (December 15 to December 21), there were 35 disclosed financing events in the global healthcare sector, with a total amount exceeding $1.15 billion.

Last week, there were four large financing deals exceeding $100 million in innovative drugs, and two new companies were established.

In the field of the central nervous system,Syremis Therapeutics Announces Official Launch and Secures $165 Million in Series A FinancingIts core pipeline, ST-905, as a novel M1/M4 muscarinic receptor agonist, has entered Phase 1 clinical trials for the treatment of schizophrenia, with the potential for once-daily oral administration and a long-acting injectable formulation. Another pipeline, ST-901, is a novel NMDA antagonist currently in the IND-enabling study stage, targeting treatment for major depressive disorder and bipolar disorder.

In the field of rare diseases,Ambros Therapeutics Announces Launch and Completion of $125 Million Series A Financing to Advance Phase 3 Clinical Trial of NeridronateThis drug is a novel bisphosphonate compound that has been granted Breakthrough Therapy, Fast Track, and Orphan Drug designations by the U.S. FDA for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1). CRPS-1 is a rare disease that often occurs after bone injuries, causing persistent severe pain in the limbs such as arms and legs. Reportedly, there are currently no approved therapies available outside of Italy.

Atavistik Bio Secures $120 Million in Series B Financing to Advance Allosteric Modulators for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPN)HHT is a severe bleeding disorder that often causes frequent bleeding, leading to chronic anemia and organ damage. Overactivation of AKT1 is a hallmark response in HHT. Atavistik Bio has developed an oral allosteric agent that selectively inhibits AKT1, overcoming the hyperglycemic toxicity associated with pan-AKT inhibitors and enhancing therapeutic potential and tolerability. For MPN, the company is selectively targeting.JAK2 V617FMutation, which is expected to reduce the burden of mutant alleles and maintain normal bone marrow function.

Addition Therapeutics Comes Out of Stealth Mode with $100 Million Series A FinancingIts PRINT platform utilizes a full RNA non-viral LNP delivery system, leveraging a retrotransposase mechanism to precisely insert therapeutic genes into ribosomal DNA safe harbor sites, with low immunogenicity. The company is currently advancing a series of pipelines for chronic and rare diseases.

Multiple Innovative Anticancer Drug Companies Secure Financing; CAR-T Therapy, Protein Degradation Therapy, and DNA Damage Response Pathway Technologies Become Focal Points.

CAR-T Newcomer Link Cell Therapies Emerges from Stealth Mode, Completes $60 Million Series A Financing, whose logic-gated technology allows for the safe targeting of multiple antigens that are selectively co-expressed on cancer cells, thereby reducing the risk of on-target, off-tumor toxicity. The core pipeline product, LNK001, is intended for the treatment of renal cell carcinoma (RCC), with plans to submit an IND application and initiate clinical trials in 2026.

T-Curx Completes $20 Million Series A Financing, focusing on acute myeloid leukemia and solid tumor indications;Yuanma Zhiyao Secures Angel+ Round Funding, which will accelerate the IIT clinical research of the in vivo CAR-T pipeline BR101 based on circular mRNA (cmRNA).

Link Cell Therapies Focuses on "Undruggable" Targets, Completes Over 200 Million Yuan in Series B Financing, will advance the Phase 1c and Phase 2 clinical trials of IRAK4 degrader LT-002 for the treatment of atopic dermatitis, hidradenitis suppurativa, and other indications; also, the Phase 1 clinical trial of KRAS G12D degrader will be initiated.

FoRx Therapeutics Completes $50 Million Series A Financing, The core pipeline FORX-428, as a PARG inhibitor, targets the DNA Damage Response (DDR) pathway, aiming to address the clinical challenge of PARP inhibitor-resistant tumors. The financing will advance the Phase 1 clinical trial.

Atavistik Bio Focuses on ADC and Multi-Specific Antibody Drug Development, Completes Nearly $50 Million FinancingThe core pipeline product ALK201 is an ADC targeting FGFR2b, planned to become the cornerstone therapy for FGFR2b-overexpressing tumors; ALK202 is an EGFR/cMET bispecific ADC intended to treat non-small cell lung cancer.

In addition, in the field of immune-related chronic diseases,Baimingxin Kang Completes Over 300 Million Yuan in D+ Round Financing；Ophthalmology Innovation Drug Company Okajan Completes $30 Million Series B FinancingIts bispecific antibody OCUL101, with a dual-target design against VEGF and complement C5, simultaneously blocks three major pathological pathways: angiogenesis, vascular leakage, and inflammatory response. It overcomes the therapeutic limitations of single-target drugs and covers three major diseases: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA), providing patients with comprehensive treatment options.

For other financings, see the table below.

Readers, please star ⭐Chuangjianhui to receive push notifications第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Innovation Insights"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommendations

Click "InSee", Share Chuangjian Hui Health New Trends